Essential Oils as Potential Anti-Influenza Agents: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jason Zhu and Version 1 by Ayodeji Oluwabunmi Oriola.

Essential oils (EOs) are chemical substances, mostly produced by aromatic plants in response to stress, that have a history of medicinal use for many diseases. In the past, EOs have continued to gain more attention because of their proven therapeutic applications against the flu and other infectious diseases. Influenza (flu) is an infectious zoonotic disease that affects the lungs and their associated organs. It is a public health problem with a huge health burden, causing a seasonal outbreak every year. Occasionally, it comes as a disease pandemic with unprecedentedly high hospitalization and mortality. Currently, iInfluenza is managed by vaccination and antiviral drugs such as Amantadine, Rimantadine, Oseltamivir, Peramivir, Zanamivir, and Baloxavir. However, the adverse side effects of these drugs, the rapid and unlimited variabilities of influenza viruses, and the emerging resistance of new virus strains to the currently used vaccines and drugs have necessitated the need to obtain more effective anti-influenza agents.

  • essential oils
  • flu-related diseases
  • influenza viruses

1. Introduction

Natural products (NPs) are chemical substances in the form of primary and secondary metabolites which are produced by living organisms such as plants, animals, marine organisms, bacteria, and fungi [1,2][1][2]. They are mostly referred to as small molecules or secondary metabolites, representing a unique scaffold of compounds that are distributed in a broad variety of chemical classes, such as alkaloids, cardiac glycosides, flavonoids, phenolics, saponins, sterols, and terpenoids [3]. Essential oil compounds form part of these classes as volatile and non-volatile aromatic substances, which comprised mostly of terpenoids and some phenylpropanoid derivatives [4,5][4][5].
Chemically, terpenoids form the largest group of essential oils, such as monoterpenes (C10) and sesquiterpenes (C15) and a few diterpenes and phenylpropanoids [6]. Many of them have functional groups such as aldehyde, ether, ester, alcohol, carboxylic acid, phenol, amines, and amides [6].
Essential oils are naturally distributed in many higher plants and are most abundant in aromatic plant families, including Lamiaceae (Peppermint family), Myrtaceae (Eucalyptus family), Rutaceae (Citrus family), and Zingiberaceae (Ginger family) [7]. They have been reported in the seeds, fruits, peels, flowers, buds, leaves, young stems, barks, resins, woods, bulbs, roots, and rhizomes of many plants [8] and are extracted by methods of hydro-distillation, steam distillation, hydro-diffusion, solvent extraction, maceration, cold-press extraction, supercritical fluid (CO2) extraction, sub-critical liquid extraction, microwave-assisted extraction, and enfleurage [4,9][4][9].
The use of EOs predates modern history. They are one of the most important NPs that have ever been utilized by many cultures, for many centuries, around the world for domestic (cosmetics, perfumery, food, and beverages) and medicinal purposes [10]. Essential oils are popularly known to help relieve the airways during the cold (winter) or flu season, and evidence has emerged of their medicinal importance in the amelioration of respiratory tract infectious diseases, such as the common cold, pneumonia, and influenza [11]. The flu (influenza) is a disease that often occurs during the winter or cold season, and so can be referred to as seasonal influenza [12].
Influenza is an infectious zoonotic respiratory disease caused by the influenza A, B, C, and D viruses, where A and B are the common virus type that causes seasonal flu [13,14][13][14]. Influenza is characterized by the sudden onset of fever, dry cough, sore throat, runny nose, headache, and joint pains [12]. It is a major public health problem, accounting for about 3–5 million cases worldwide, with about a 10% annual death rate [12]. It is responsible for high hospitalization and deaths among high-risk individuals, such as the elderly and those with co-morbidities [15].
Vaccination remains a primary strategy to prevent and control influenza, due to the waning immunity that is associated with it [16]. So far, an effort made to reduce the burden of influenza through the administration of vaccines has yielded promising results, with more expectations for success. Vaccine selectivity is still a major issue because the currently available influenza vaccines are virus-type- and sub-type-specific [17]. In addition, many people are still in doubt about the harmlessness of vaccines due to cultural beliefs, myths, and conspiracy theories, thus causing vaccine hesitancy [18]. Therefore, there is a need for deliberate and continuous vaccine education and advocacy to help bring influenza to a halt.
Currently, four FDA-approved antiviral drugs of three different classes are recommended for use against the recently circulating influenza viruses, Baloxavir marboxil, Oseltamivir, Peramivir, and Zanamivir [19]. Despite the availability of these drugs, influenza is still on the rampage, taking its toll on human health and well-being. In fact, the problem is further exacerbated because the available drugs still lack strong antiviral activity against all the influenza virus strains; in addition, there is always an emergence of new resistant strains and the resurgence of old virulent strains that were not adequately reduced in past influenza outbreaks [20].

2. Influenza (Flu)

Influenza is a contagious viral disease that affects the upper and lower respiratory tract [92][21]. Influenza viruses can be found in humans and some animals such as Aves and cattle, and are generally categorized as type A, B, C, and D influenza viruses [93,94][22][23]. The common types are the influenza A and B viruses, which affect humans and are mostly characterized as the seasonal flu [92][21]. Influenza A viruses are largely implicated in the flu pandemic and are a common cause of zoonotic infections, often characterized by virulent infections in humans [14,95][14][24]. The influenza C viruses are predominantly responsible for mild illness in animals and are rarely implicated in human epidemics [14,95][14][24]. Influenza D viruses mostly affect animals, with rare cases of human-to-human transmission [93][22]. Symptoms associated with influenza virus infections include a fever, sore throat, runny nose, cough, fatigue, and headache, owing to disease of the upper respiratory tract, while the lower respiratory tract may present with severe or acute pneumonia [96][25]. The influenza disease caused by the type A influenza virus of zoonotic origin, is a major public health concern, as it is responsible for both the common seasonal influenza epidemic (seasonal flu) and the sporadic and unpredictable (10–50 years of occurrence) global influenza pandemic outbreaks [97][26]. Seasonal influenza outbreaks typically occur during the winter season in temperate regions (Europe, Southern Africa), due to favourable conditions of low humidity and low temperatures [97,98][26][27]. However, in tropical countries, it is characterized by a complex pattern of occurrences due to an interplay of climatic factors such as temperature levels, hours of sunshine, and the level of rainfall [98][27]. On the other hand, pandemic influenza is characterized by a fast spread of the influenza A virus from the virus origin to the rest of the world in several waves over a short period, as witnessed in the first influenza pandemic of 1918 by the influenza A H1N1 virus strain, and subsequent pandemics of 1957, 1968, and 2009, caused by the Influenza A H2N2, H3N2, and H1N1 virus strains, respectively [97,99][26][28]. According to the World Health Organization, up to 1 billion influenza virus infection cases are reported annually, with about 4 million of the cases leading to severe illness, and around 400,000 reported deaths [95][24]. The most vulnerable groups are often infants between the ages of 0–9 months and adults 65-years-old and above [100][29]. Vaccination remains an effective means to reduce the burden of influenza [101][30]. The National Advisory Committee on Immunization (NACI) recommended the use of two classes of influenza vaccines, the Inactivated Influenza Vaccines (IIVs) and the Live Attenuated Influenza Vaccines (LAIVs) [102][31]. Just prior to the COVID-19 pandemic, it was reported that vaccination prevented an estimated 3.7 million cases of influenza, 105,000 influenza-related hospitalizations, and 6300 influenza-associated deaths worldwide [103][32]. However, more success in flu vaccination is still desired. Some key issues to be addressed include the complexity involved in predicting the pattern of seasonal influenza, reduced vaccine efficacy based on repeated annual immunization, an antigenic mismatch between the developed vaccines and the circulating virus strains, an age difference of the different cohorts involved in vaccination, and the issue of variability in the virulence level of different seasonal strains of the virus [104,105,106][33][34][35]. Even though vaccination is the most effective means of reducing the burden of influenza, antiviral drugs can be very useful in delaying the spread of new pandemic viruses, and they have also been found useful for the treatment of critically ill influenza patients [107][36]. There have been significant strides in the development of influenza antiviral drugs (IADs), and there are currently three classes of FDA-approved IADs: M2 proton channel antagonists, neuraminidase inhibitors, and polymerase acidic endonuclease inhibitors [108][37]. The drugs Amantadine and Rimantadine, are M2 proton channel antagonists, which used to be effective for the treatment of influenza A virus infection but have lost their efficacies over the years due to the emergence of more virulent strains of the type A virus, such as the 2009 H1N1 influenza A virus [19]. The FDA-approved neuraminidase inhibitors such as Oseltamivir, Peramivir, and Zanamivir are more efficacious and less toxic for the management of influenza than the M2 proton channel antagonists [109][38]. However, these drugs are associated with adverse effects, such as skin rash, diarrhea, anaphylactic reaction, headache, nausea, vomiting, cough, and gastritis [108][37]. Baloxavir is a cap-dependent, polymerase acidic endonuclease inhibitor which is similar in potency to neuraminidase inhibitors, except for the fact that it is newer and offers a different mechanism of action from the earlier developed neuraminidase inhibitory drugs [108,110][37][39]. Based on the rapid and unlimited variabilities of influenza viruses and the emerging resistance of new influenza virus strains to the currently used drugs, there is a dire need to discover more lead anti-influenza agents with a novel mechanism of action and develop (synthesize and optimize) more effective analogs from the already existing ones [109][38]. Natural products, including EOs, continue to offer an inexhaustible reservoir of bioactive compounds as lead therapeutic agents for the management of diseases. Some EOs and their compounds have been reported to demonstrate remarkable biological activities against a wide range of viruses, including influenza viruses [111][40]. It is against this backdrop that the anti-influenza potentials of EOs and their compounds were discussed, vis a viz the mechanism of action and structure-activity relationships of lead antiviral compounds, to source newer anti-influenza agents.

3. Anti-Influenza Properties of Plant-Derived Essential Oils and Their Compounds

Evidence has emerged on the anti-influenza potentials of many aromatic plants that are used for the treatment of flu and flu symptoms (cold, cough, sore throat, bronchitis, and pneumonia) by various ethnomedicines [112][41]. For instance, the EOs of Cynanchum stauntonii roots demonstrated an in vitro activity against Influenza A/NWS/33 (H1N1) virus at an IC50 value of 64 µg/mL and selectivity index of 8, with the main EOs used comprising (E,E)-2,4-decadienal, 3-ethyl-4-methypentanol, 5-pentyl-3H-furan-2-one, (E,Z)-2,4-decadienal, 2(3H)-furanone,dihydro-5-pentyl, and caryophyllene oxide [113][42]. Further investigation revealed considerable inhibitory effects on influenza-induced deaths with 40, 70, and 100% survival rates when administered 50, 150, and 300 mg/kg doses of the EO, respectively, in male albino mice [113][42]. The leaf EOs of Melaleuca alternifolia (tea tree oil) contain terpinen-4-ol, terpinolene, and α-terpineol, which showed considerable in vitro activity against the influenza A virus in MDCK cells by interference with acidification of intra-lysosomal compartment [114][43]. Mosla dianthera is an aromatic herb used in the TCM to treat colds, coughs, nasal congestion, bronchitis, fever, and headache [115][44]. The EOs derived from the aerial part of M. dianthera exhibited significant in vivo inhibitory activity against the influenza A virus at 90–360 mg/kg body weight in mice, with elemicin, thymol, β-caryophyllene, iso-elemicin, asarone, and α-caryophyllene implicated as the major active ingredients [112][41].
The in vitro antiviral activities of Citrus bergamia and Eucalyptus globulus EOs against the influenza A H1N1 virus have also been reported, in which E. globulus vapor EOs reduced viral infection by 78%, with no cytotoxicity, while that of C. bergamia reduced the viral cytopathic effect with no cytotoxicity [116][45]. The major EOs characterized in the former are limonene, linalyl acetate, and linalool, while the latter contained 1,8-cineole, γ-terpinene, p-cymene, and α-thujene [116][45]. In addition, thujone- and α-pinene rich Cedar (Thuja plicata) EO vapor demonstrated over 90% inhibitory activities against some membrane-containing influenza A H1N1 and H3N2 and B viruses within 10 min of exposure to the viruses in vitro [117][46].

4. Mechanisms of Action and Structure-Activity Relationships of Some Lead Anti-Influenza Essential Oil Compounds

Basically, the molecular mechanisms of action of lead anti-influenza agents can be summed up under two major categories: those agents that target influenza virus proteins or genes and those that target the various components within the hosts for replication and propagation [107][36]. These mechanisms can be used to further categorize anti-influenza agents (virus inhibitors). First, entry and attachment (fusion) inhibitors, which are commonly used as an adjuvant in the preparation of anti-influenza vaccines [132,133][47][48]. The aerial EO of Melaleuca alternifolia, known as tea tree oil (TTO), has been shown in an in silico simulation study to interfere with the entry and fusion activities of the influenza virus [116][45]. The anti-influenza activity has been attributed to its hydroxylated monoterpenes, terpinen-4-ol, and α-terpineol [114][43]. Other known groups are hemagglutinin inhibitors [134][49], M2 ion channel protein inhibitors [135][50], endosomal and lysosomal inhibitors, also implicated in the TTO [125][51], protease inhibitors [136][52], RNA polymerase inhibitors [137][53], pathway inhibitors [138][54], neuraminidase inhibitors [139][55], non-structural protein inhibitors [107][36], caspase inhibitors [140][56], glycoprotein/glycosylation inhibitors [141][57], phospholipase inhibitors [142][58], release inhibitors [143[59][60],144], and autophagy [145][61]. Natural antiviral agents including EO compounds can act as inhibitors during the influenza virus activity stages of binding, penetration, uncoating, genome replication, assembly, and release of the virus; thus, they may offer considerable protection and efficacy as anti-influenza agents [146][62]. Three major compounds, curdione, curcumol, and germacrone, were implicated in the antiviral EO components of the TCM Zedoary oil [147][63]. The compounds impaired influenza A (H1N1) virus replication in vitro and in vivo, with germacrone exhibiting the highest anti-H1N1 effect [147][63]. Germacrone was shown to activate the transcription of interferon genes and protect the peripheral cells from influenza virus infections [147][63]. It also showed a marked decrease in the expression of antiviral proteins, RIG-I, IFNs, OAS, IRF3/7, MX, and EIF2AK2/PKR, viral replication, and viral load, with increased TAP1 expression, inhibited TAK1 phosphorylation, and consequently inhibited the NF-κB signaling and intrinsic antiviral responses [147,148][63][64]. The biological properties of germacrone have been linked to its ketone and non-conjugated double bonds [149][65]. Some anti-influenza active bisabolane-type sesquiterpenoids from turmeric oil (Curcuma longa) have also been reported [150][66]. Generally, turmeric oil is used in ethnomedicine for the treatment of flu-related and/or airway inflammatory diseases, such as bronchitis, pneumonia, and influenza [151][67]. The compounds significantly acted as pathway inhibitors against the influenza A/PR/8/34 (H1N1) virus replication in MDCK and A549 cells in vitro [150][66]. The compounds act by inhibiting the expression of pro-inflammatory cytokines (IL-6, IL-8, IP-10, and TNF-α), and regulating the activity of the NF-κB/MAPK and RIG-1/STAT-1/2 signaling pathways [150][66]. The presence of ketone, α, β-unsaturation, and presence of an electron-withdrawing group (OH, OCH3, NH2, SH, and halogens) have been reported to influence the bioactivity of this group of compounds. Eucalyptol (1,8-cineole), a monoterpenoid principally from Eucalyptus plants, is another lead anti-influenza agent to discuss [153][68]. Eucalyptus oil is used in traditional medicines as a remedy for respiratory ailments [154][69]. Eucalyptol is a major EO component of the oil, and it has been shown to exert considerable protection against influenza viral infection in vivo [155][70]. The oil efficiently decreased the levels of cytokines, IL-4, IL-5, IL-10, and MCP-1 in nasal lavage fluids, as well as the levels of IL-1β, IL-6, and necrosis factors TNF-α and IFN-γ in the lung tissues of mice infected with the influenza A virus [153][68]. It also reduced the expression of the inflammatory response, NF-kB, p65, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1 in lung tissues [154][69]. The findings thus suggest that eucalyptol is capable of augmenting protection against influenza virus infection in mice by inhibiting pulmonary inflammatory responses in the tissues [154][69]. In another study, eucalyptol (12.5 mg/kg) demonstrated lower viral titers, less pulmonary edema, less weight loss, less inflammation, a lower mortality rate, and a longer survival time when it was co-administered with 0.2 µg of haemagglutinin influenza vaccine, compared to when the vaccine was administered alone [156][71]. The mechanism of action of eucalyptol has been reported to be an increase in the antiviral activity of IRF3 as well as the IκBα- and JNK-dependent inhibitory effect of IRF3 on the NF-κB p65 and NF-κB proinflammatory signaling pathways [156,157][71][72]. The presence of an epoxy functional group and the unique inter-atomic distance between the R1-C-O-C-R2 of eucalyptol have been linked to its remarkable biological effects [158][73]. In a recent study, isocaryophyllene acetamides (ICAs) and some S-containing derivatives of caryophyllene oxide (caryophyllane thiosesquiterpenoid, CTS) were shown to inhibit the replication of rimantadine-resistant influenza virus A/California/07/09 (H1N1) pdm09 and influenza virus A/Puerto Rico/8/34 (H1N1) strains, respectively [159,160][74][75]. Due to the natural bicyclic framework of ICAs (they are known to show marked anti-influenza activity by blocking the M2 protein of the influenza virus and by inhibiting the cleavage of hemagglutinin [160][75]. This led to an aggregation of the virus and lysosomal vacuole membranes and virus inactivation [160][75]. Gyrdymova and others demonstrated the influence of the S-containing functional group on anti-influenza activity, showing that bisulfide-containing CTS compounds possess high virus-inhibitory activities and suggesting S-containing derivatives of caryophyllene oxide as promising substrates for the design of newer anti-influenza and/or antiviral agents [161][76]. Some caryophyllene derivatives (Ginsamides, GAs) were reported to demonstrate dose-dependent virus inhibition and subtype-specific virus-inhibiting activity (IC50 = 0.15 µM) against the influenza virus H1N1 and H1N1pdm09 strains in a pool of influenza virus A/Puerto Rico/8/34 (H1N1) strains in MDCK in vitro cell cultures [162][77]. Ginsamides showed considerable in vivo protective ability against the virus at 150 mg/kg/day and inhibited the fusogenic activity that is typical of influenza A/Puerto Rico/8/34 (H1N1) viruses [163][78]. According to the report, GAs can act as lead inhibitors against the viral infection of normal cells and may offer the host an opportunity to maintain a complete immune response [162,164][77][79]. Structurally, the bicyclic backbone and the amide functional group of GAs are known to confer a high level of antiviral and anti-influenza activities [107,161,163][36][76][78]. Eugenol and citronellol are major EO compounds of Cinnamomum zeylanicum and Pelargonium graveolense, respectively [165,166][80][81]. The combined EOs demonstrated in vitro antiviral activity (MIC = 100 3.1 µL/mL) against the influenza A (H1N1) virus [167][82]. It acted by targeting the virus surface before and during the adsorption event in the viral lifecycle, thus making it a natural neuraminidase inhibitor [167][82]. Structurally, eugenol and citronellol contain phenolic hydroxyl and primary alcohol functional groups, respectively, which confer some biological properties, such as antioxidant, anti-inflammatory, and antiviral activities, amongst others [168,169][83][84]. A novel camphor-based anti-influenza agent, camphecene, has been reported to cause a significant decrease in the number of influenza virions fusing their envelopes with endosomal membranes [170][85]. This nitrogen-containing camphor derivative has been reported to possess unique chemical properties that bind it effectively to the active sites of hemagglutinin (HA), acting as an HA inhibitor, and thus causing a decrease in viral pathogenicity [170][85]. Based on the pharmacokinetic study, camphecene demonstrated a remarkable decrease in virus titer in the lungs and mortality at 7.5 mg/kg, following a 6 h dose regime in vivo [171][86]. It also demonstrated an additive effect with Tamiflu, a synthetic anti-influenza drug, which suggests it is an anti-influenza drug candidate [170,171][85][86]. Several analogs of this compound have been synthesized, and the structure-activity relationship analysis suggests that camphecene analogs should bear an oxygen atom with a short linker (C2–C4), either as a hydroxyl or ketone group, or as part of a heterocycle, for optimal anti-influenza activity [172][87].
 

References

  1. Bruce, O.S.; Onyegbule, A.F. Biosynthesis of Natural Products. In Bioactive Compounds-Biosynthesis, Characterization and Applications; Zepka, L.Q., Nascimento, T.C.d., Jacob-Lopes, E., Eds.; IntechOpen: London, UK, 2021; 304p, Available online: https://www.intechopen.com/books/10290 (accessed on 10 October 2022).
  2. Ntie-Kang, F.; Svozil, D. An Enumeration of Natural Products from Microbial, Marine and Terrestrial Sources. Phys. Sci. Rev. 2020, 5, 20180121.
  3. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661.
  4. Aziz, Z.A.A.; Ahmad, A.; Setapar, S.H.M.; Karakucuk, A.; Azim, M.M.; Lokhat, D.; Rafatullah, M.; Ganash, M.; Kamal, M.A.; Ashraf, G.M. Essential Oils: Extraction Techniques, Pharmaceutical and Therapeutic Potential—A Review. Curr. Drug Metab. 2018, 19, 1100–1110.
  5. Stephane, F.F.Y.; Jules, B.K.J. Terpenoids as Important Bioactive Constituents of Essential Oils. Essent. Oils—Bioact. Compd. New Perspect. Appl. 2020.
  6. Dhifi, W.; Bellili, S.; Jazi, S.; Bahloul, N.; Mnif, W. Essential Oils’ Chemical Characterization and Investigation of Some Biological Activities: A Critical Review. Medicines 2016, 3, 25.
  7. Baser, K.H.C.; Butchbauer, G. Handbook of Essential Oils: Science, Technology and Applications; CRC Press: Boca Raton, FL, USA, 2009; p. 978042914.
  8. Medicinal Plant Research in Africa: Pharmacology and Chemistry—Ghent University Library. Available online: https://lib.ugent.be/catalog/ebk01:2550000001064753 (accessed on 6 August 2022).
  9. Stratakos, A.C.; Koidis, A. Methods for Extracting Essential Oils. In Essential Oils in Food Preservation, Flavor and Safety; Academic Press: Cambridge, MA, USA, 2016; pp. 31–38.
  10. Elshafie, H.S.; Camele, I. An Overview of the Biological Effects of Some Mediterranean Essential Oils on Human Health. Biomed. Res. Int. 2017, 2017, 9268468.
  11. Horváth, G.; Ács, K. Essential Oils in the Treatment of Respiratory Tract Diseases Highlighting Their Role in Bacterial Infections and Their Anti-inflammatory Action: A Review. Flavour Fragr. J. 2015, 30, 331.
  12. Influenza (Seasonal). Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (accessed on 6 August 2022).
  13. Key Facts about Influenza (Flu)|CDC. Available online: https://www.cdc.gov/flu/about/keyfacts.htm (accessed on 6 August 2022).
  14. Types of Influenza Viruses|CDC. Available online: https://www.cdc.gov/flu/about/viruses/types.htm (accessed on 7 August 2022).
  15. Wu, P.; Presanis, A.M.; Bond, H.S.; Lau, E.H.Y.; Fang, V.J.; Cowling, B.J. A Joint Analysis of Influenza-Associated Hospitalizations and Mortality in Hong Kong, 1998–2013. Sci. Rep. 2017, 7, 929.
  16. Senthur Nambi, P.; Suresh Kumar, D.; Gopalakrishnan, R. Influenza Vaccine. Indian J. Pract. Pediatr. 2022, 12, 372–377.
  17. Selecting Viruses for the Seasonal Influenza Vaccine|CDC. Available online: https://www.cdc.gov/flu/prevent/vaccine-selection.htm (accessed on 7 August 2022).
  18. Ullah, I.; Khan, K.S.; Tahir, M.J.; Ahmed, A.; Harapan, H. Myths and Conspiracy Theories on Vaccines and COVID-19: Potential Effect on Global Vaccine Refusals. Vacunas 2021, 22, 93.
  19. Influenza (Flu) Antiviral Drugs and Related Information|FDA. Available online: https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information (accessed on 7 August 2022).
  20. Yin, H.; Jiang, N.; Shi, W.; Chi, X.; Liu, S.; Chen, J.L.; Wang, S. Development and Effects of Influenza Antiviral Drugs. Molecules 2021, 26, 810.
  21. Boktor, S.W.; Hafner, J.W. Influenza. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.
  22. Glezen, W.P. Emerging Infections: Pandemic Influenza. Epidemiol. Rev. 1996, 18, 64–76.
  23. Yang, L.; Chan, K.P.; Wong, C.M.; Chiu, S.S.S.; Magalhaes, R.J.S.; Thach, T.Q.; Peiris, J.S.M.; Clements, A.C.A.; Hu, W. Comparison of Influenza Disease Burden in Older Populations of Hong Kong and Brisbane: The Impact of Influenza and Pneumococcal Vaccination. BMC Infect. Dis. 2019, 19, 162.
  24. Hagey, R.J.; Elazar, M.; Pham, E.A.; Tian, S.; Ben-Avi, L.; Bernardin-Souibgui, C.; Yee, M.F.; Moreira, F.R.; Rabinovitch, M.V.; Meganck, R.M.; et al. Programmable Antivirals to Target Conserved Essential Shapes in Pandemic Viral Genomes. Nat. Med. 2022, 28, 1944–1955.
  25. Sellers, S.A.; Hagan, R.S.; Hayden, F.G.; Fischer, W.A. The Hidden Burden of Influenza: A Review of the Extra-Pulmonary Complications of Influenza Infection. Influenza Other Respir. Viruses 2017, 11, 372–393.
  26. Krammer, F.; Smith, G.J.D.; Fouchier, R.A.M.; Peiris, M.; Kedzierska, K.; Doherty, P.C.; Palese, P.; Shaw, M.L.; Treanor, J.; Webster, R.G.; et al. Influenza. Nat. Rev. Dis. Prim. 2018, 4, 1–21.
  27. Yu, H.; Alonso, W.J.; Feng, L.; Tan, Y.; Shu, Y.; Yang, W.; Viboud, C. Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data. PLoS Med. 2013, 10, e1001552.
  28. Palese, P.; Tumpey, T.M.; Garcia-Sastre, A. What Can We Learn from Reconstructing the Extinct 1918 Pandemic Influenza Virus? Immunity 2006, 24, 121–124.
  29. Iuliano, A.D.; Roguski, K.M.; Chang, H.H.; Muscatello, D.J.; Palekar, R.; Tempia, S.; Cohen, C.; Gran, J.M.; Schanzer, D.; Cowling, B.J.; et al. Estimates of Global Seasonal Influenza-Associated Respiratory Mortality: A Modelling Study. Lancet 2018, 391, 1285–1300.
  30. Global Influenza Programme. Available online: https://www.who.int/teams/global-influenza-programme/vaccines (accessed on 13 September 2022).
  31. Young, K.; Gemmill, I.; Harrison, R. Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021. Can. Commun. Dis. Rep. 2020, 46, 132–137.
  32. Seasonal Flu Vaccines|CDC. Available online: https://www.cdc.gov/flu/prevent/flushot.htm (accessed on 13 September 2022).
  33. Paules, C.I.; Sullivan, S.G.; Subbarao, K.; Fauci, A.S. Chasing Seasonal Influenza—The Need for a Universal Influenza Vaccine. N. Engl. J. Med. 2018, 378, 7–9.
  34. Saito, N.; Komori, K.; Suzuki, M.; Morimoto, K.; Kishikawa, T.; Yasaka, T.; Ariyoshi, K. Negative Impact of Prior Influenza Vaccination on Current Influenza Vaccination among People Infected and Not Infected in Prior Season: A Test-Negative Case-Control Study in Japan. Vaccine 2017, 35, 687–693.
  35. DiazGranados, C.A.; Denis, M.; Plotkin, S. Seasonal Influenza Vaccine Efficacy and Its Determinants in Children and Non-Elderly Adults: A Systematic Review with Meta-Analyses of Controlled Trials. Vaccine 2012, 31, 49–57.
  36. Gasparini, R.; Amicizia, D.; Lai, P.L.; Bragazzi, N.L.; Panatto, D. Compounds with Anti-Influenza Activity: Present and Future of Strategies for the Optimal Treatment and Management of Influenza Part II: Future Compounds against Influenza Virus. J. Prev. Med. Hyg. 2014, 55, 109.
  37. Świerczyńska, M.; Mirowska-Guzel, D.M.; Pindelska, E. Antiviral Drugs in Influenza. Int. J. Environ. Res. Public Health 2022, 19, 3018.
  38. Doll, M.K.; Winters, N.; Boikos, C.; Kraicer-Melamed, H.; Gore, G.; Quach, C. Safety and Effectiveness of Neuraminidase Inhibitors for Influenza Treatment, Prophylaxis, and Outbreak Control: A Systematic Review of Systematic Reviews and/or Meta-Analyses. J. Antimicrob. Chemother. 2017, 72, 2990–3007.
  39. Hayden, F.G.; Shindo, N. Influenza Virus Polymerase Inhibitors in Clinical Development. Curr. Opin. Infect. Dis. 2019, 32, 176.
  40. Asif, M.; Saleem, M.; Saadullah, M.; Yaseen, H.S.; al Zarzour, R. COVID-19 and Therapy with Essential Oils Having Antiviral, Anti-Inflammatory, and Immunomodulatory Properties. Inflammopharmacology 2020, 28, 1153.
  41. Wu, Q.F.; Wang, W.; Dai, X.Y.; Wang, Z.Y.; Shen, Z.H.; Ying, H.Z.; Yu, C.H. Chemical Compositions and Anti-Influenza Activities of Essential Oils from Mosla dianthera. J. Ethnopharmacol. 2012, 139, 668–671.
  42. Zai-Chang, Y.; Bo-Chu, W.; Xiao-Sheng, Y.; Qiang, W. Chemical Composition of the Volatile Oil from Cynanchum stauntonii and Its Activities of Anti-Influenza Virus. Colloids Surf. B Biointerfaces 2005, 43, 198–202.
  43. Garozzo, A.; Timpanaro, R.; Stivala, A.; Bisignano, G.; Castro, A. Activity of Melaleuca alternifolia (Tea Tree) Oil on Influenza Virus A/PR/8: Study on the Mechanism of Action. Antivir. Res. 2011, 89, 83–88.
  44. Lee, D.H.; Kim, S.H.; Eun, J.S.; Shin, T.Y. Mosla dianthera Inhibits Mast Cell-Mediated Allergic Reactions through the Inhibition of Histamine Release and Inflammatory Cytokine Production. Toxicol. Appl. Pharmacol. 2006, 216, 479–484.
  45. Madia, V.N.; Toscanelli, W.; de Vita, D.; de Angelis, M.; Messore, A.; Ialongo, D.; Scipione, L.; Tudino, V.; D’auria, F.D.; di Santo, R.; et al. Ultrastructural Damages to H1N1 Influenza Virus Caused by Vapor Essential Oils. Molecules 2022, 27, 3718.
  46. Selvarani, V.; James, H. The Activity of Cedar Leaf Oil Vapor against Respiratory Viruses: Practical Applications. J. Appl. Pharm. Sci. 2013, 3, 11–15.
  47. Scherließ, R.; Ajmera, A.; Dennis, M.; Carroll, M.W.; Altrichter, J.; Silman, N.J.; Scholz, M.; Kemter, K.; Marriott, A.C. Induction of Protective Immunity against H1N1 Influenza A(H1N1)Pdm09 with Spray-Dried and Electron-Beam Sterilised Vaccines in Non-Human Primates. Vaccine 2014, 32, 2231–2240.
  48. Luo, G.; Torri, A.; Harte, W.E.; Danetz, S.; Cianci, C.; Tiley, L.; Day, S.; Mullaney, D.; Yu, K.L.; Ouellet, C.; et al. Molecular Mechanism Underlying the Action of a Novel Fusion Inhibitor of Influenza A Virus. J. Virol. 1997, 71, 4062–4070.
  49. Yoshimoto, J.; Kakui, M.; Iwasaki, H.; Fujiwara, T.; Sugimoto, H.; Hattori, N. Identification of a Novel HA Conformational Change Inhibitor of Human Influenza Virus. Arch. Virol. 1999, 144, 865–878.
  50. Wang, J.; Wu, Y.; Ma, C.; Fiorin, G.; Wang, J.; Pinto, L.H.; Lamb, R.A.; Klein, M.L.; DeGrado, W.F. Structure and Inhibition of the Drug-Resistant S31N Mutant of the M2 Ion Channel of Influenza A Virus. Proc. Natl. Acad. Sci. USA 2013, 110, 1315–1320.
  51. Garozzo, A.; Timpanaro, R.; Bisignano, B.; Furneri, P.M.; Bisignano, G.; Castro, A. In Vitro Antiviral Activity of Melaleuca alternifolia Essential Oil. Lett. Appl. Microbiol. 2009, 49, 806–808.
  52. Bahgat, M.M.; Bazejewska, P.; Schughart, K. Inhibition of Lung Serine Proteases in Mice: A Potentially New Approach to Control Influenza Infection. Virol. J. 2011, 8, 27.
  53. Loregian, A.; Mercorelli, B.; Nannetti, G.; Compagnin, C.; Palù, G. Antiviral Strategies against Influenza Virus: Towards New Therapeutic Approaches. Cell. Mol. Life Sci. 2014, 71, 3659–3683.
  54. Planz, O. Development of Cellular Signaling Pathway Inhibitors as New Antivirals against Influenza. Antivir. Res. 2013, 98, 457–468.
  55. Li, J.; Zhang, D.; Zhu, X.; He, Z.; Liu, S.; Li, M.; Pang, J.; Lin, Y. Studies on Synthesis and Structure-Activity Relationship (SAR) of Derivatives of a New Natural Product from Marine Fungi as Inhibitors of Influenza Virus Neuraminidase. Mar. Drugs 2011, 9, 1887–1901.
  56. Feldman, T.; Kabaleeswaran, V.; Jang, S.B.; Antczak, C.; Djaballah, H.; Wu, H.; Jiang, X. A Class of Allosteric Caspase Inhibitors Identified by High-Throughput Screening. Mol. Cell 2012, 47, 585–595.
  57. Muniruzzaman, S.; Pan, Y.T.; Zeng, Y.; Atkins, B.; Izumori, K.; Elbein, A.D. Inhibition of Glycoprotein Processing by L-Fructose and L-Xylulose. Glycobiology 1996, 6, 795–803.
  58. Oguin, T.H.; Sharma, S.; Stuart, A.D.; Duan, S.; Scott, S.A.; Jones, C.K.; Daniels, J.S.; Lindsley, C.W.; Thomas, P.G.; Brown, H.A. Phospholipase D Facilitates Efficient Entry of Influenza Virus, Allowing Escape from Innate Immune Inhibition. J. Biol. Chem. 2014, 289, 25405–25417.
  59. Hsieh, C.F.; Lo, C.W.; Liu, C.H.; Lin, S.; Yen, H.R.; Lin, T.Y.; Horng, J.T. Mechanism by Which Ma-Xing-Shi-Gan-Tang Inhibits the Entry of Influenza Virus. J. Ethnopharmacol. 2012, 143, 57–67.
  60. Hsieh, C.F.; Yen, H.R.; Liu, C.H.; Lin, S.; Horng, J.T. Ching-Fang-Pai-Tu-San Inhibits the Release of Influenza Virus. J. Ethnopharmacol. 2012, 144, 533–544.
  61. Dai, J.; Wang, G.; Li, W.; Zhang, L.; Yang, J.; Zhao, X.; Chen, X.; Xu, Y.; Li, K. High-Throughput Screening for Anti-Influenza A Virus Drugs and Study of the Mechanism of Procyanidin on Influenza A Virus-Induced Autophagy. J. Biomol. Screen. 2012, 17, 605–617.
  62. Ma, L.; Yao, L. Antiviral Effects of Plant-Derived Essential Oils and Their Components: An Updated Review. Molecules 2020, 25, 2627.
  63. Li, L.; Xie, Q.; Bian, G.; Zhang, B.; Wang, M.; Wang, Y.; Chen, Z.; Li, Y. Anti-H1N1 Viral Activity of Three Main Active Ingredients from Zedoary Oil. Fitoterapia 2020, 142, 104489.
  64. Xia, Z.; Xu, G.; Yang, X.; Peng, N.; Zuo, Q.; Zhu, S.; Hao, H.; Liu, S.; Zhu, Y. Inducible TAP1 Negatively Regulates the Antiviral Innate Immune Response by Targeting the TAK1 Complex. J. Immunol. 2017, 198, 3690–3704.
  65. Galisteo Pretel, A.; Pérez Del Pulgar, H.; Guerrero de León, E.; López-Pérez, J.L.; Olmeda, A.S.; Gonzalez-Coloma, A.; Barrero, A.F.; Quílez Del Moral, J.F. Germacrone Derivatives as New Insecticidal and Acaricidal Compounds: A Structure-Activity Relationship. Molecules 2019, 24, 2898.
  66. Ti, H.; Mai, Z.; Wang, Z.; Zhang, W.; Xiao, M.; Yang, Z.; Shaw, P. Bisabolane-Type Sesquiterpenoids from Curcuma longa L. Exert Anti-Influenza and Anti-Inflammatory Activities through NF-ΚB/MAPK and RIG-1/STAT1/2 Signaling Pathways. Food Funct. 2021, 12, 6697–6711.
  67. Toden, S.; Theiss, A.L.; Wang, X.; Goel, A. Essential Turmeric Oils Enhance Anti-Inflammatory Efficacy of Curcumin in Dextran Sulfate Sodium-Induced Colitis. Sci. Rep. 2017, 7, 816.
  68. Ait-Ouazzou, A.; Lorán, S.; Bakkali, M.; Laglaoui, A.; Rota, C.; Herrera, A.; Pagán, R.; Conchello, P. Chemical Composition and Antimicrobial Activity of Essential Oils of Thymus algeriensis, Eucalyptus globulus and Rosmarinus officinalis from Morocco. J. Sci. Food Agric. 2011, 91, 2643–2651.
  69. Li, Y.; Lai, Y.; Wang, Y.; Liu, N.; Zhang, F.; Xu, P. 1,8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice. Inflammation 2016, 39, 1582–1593.
  70. Juergens, U.R.; Stöber, M.; Vetter, H. Inhibition of Cytokine Production and Arachidonic Acid Metabolism by Eucalyptol (1.8-Cineole) in Human Blood Monocytes in Vitro. Eur. J. Med. Res. 1998, 3, 508–510.
  71. Mieres-Castro, D.; Ahmar, S.; Shabbir, R.; Mora-Poblete, F. Antiviral Activities of Eucalyptus Essential Oils: Their Effectiveness as Therapeutic Targets against Human Viruses. Pharmaceuticals 2021, 14, 1210.
  72. Müller, J.; Greiner, J.F.W.; Zeuner, M.; Brotzmann, V.; Schäfermann, J.; Wieters, F.; Widera, D.; Sudhoff, H.; Kaltschmidt, B.; Kaltschmidt, C. 1,8-Cineole Potentiates IRF3-Mediated Antiviral Response in Human Stem Cells and in an Ex Vivo Model of Rhinosinusitis. Clin. Sci. 2016, 130, 1339–1352.
  73. Villecco, M.B.; Catalán, J.v; Vega, M.I.; Garibotto, F.M.; Enriz, R.D.; Catalán, C.A.N. Synthesis and Antibacterial Activity of Highly Oxygenated 1,8-Cineole Derivatives. Nat. Prod. Commun. 2008, 3, 1934578X0800300301.
  74. Yarovaya, O.I.; Stro, A.A.; Orshanskaya, Y.R.; Zarubaev, V.V.; Khazanov, V.A.; Salakhutdinov, N.F. (1S,3aR,4R,7aS)-N-(2,2,4,7a-Tetramethyloctahydro-1,4-ethanoindene-3a-yl)-acetamide Application as a Influenza Virus Reproduction Inhibitor. RU2616255C1, 13 April 2017.
  75. Gyrdymova, Y.v.; Sinegubova, E.O.; Muryleva, A.S.; Zarubaev, V.v.; Rubtsova, S.A. Anti-Influenza Activity of Several Caryophyllane Hiosesquiterpenoids. Chem. Nat. Compd. 2019, 55, 1179–1181.
  76. Scholtissek, C.; Quack, G.; Klenk, H.D.; Webster, R.G. How to Overcome Resistance of Influenza A Viruses against Adamantane Derivatives. Antivir. Res. 1998, 37, 83–95.
  77. Volobueva, A.S.; Yarovaya, O.I.; Kireeva, M.v.; Borisevich, S.S.; Kovaleva, K.S.; Mainagashev, I.Y.; Gatilov, Y.v.; Ilyina, M.G.; Zarubaev, V.v.; Salakhutdinov, N.F. Discovery of New Ginsenol-Like Compounds with High Antiviral Activity. Molecules 2021, 26, 6794.
  78. Hayden, F.G.; Pavia, A.T. Antiviral Management of Seasonal and Pandemic Influenza. J. Infect. Dis. 2006, 194, S119–S126.
  79. Plotch, S.J.; O’Hara, B.; Morin, J.; Palant, O.; LaRocque, J.; Bloom, J.D.; Lang, S.A.; DiGrandi, M.J.; Bradley, M.; Nilakantan, R.; et al. Inhibition of Influenza A Virus Replication by Compounds Interfering with the Fusogenic Function of the Viral Hemagglutinin. J. Virol. 1999, 73, 140–151.
  80. Rana, V.S.; Juyal, J.P.; Blazquez, M.A. Chemical Constituents of Essential Oil of Pelargonium graveolens Leaves. Int. J. Aromather. 2002, 4, 216–218.
  81. Paranagama, P.A.; Wimalasena, S.; Jayatilake, G.S.; Jayawardena, A.L.; Senanayake, U.M.; Mubarak, A.M. A Comparison of Essential Oil Constituents of Bark, Leaf, Root and Fruit of Cinnamon (Cinnamomum zeylanicum Blum) Grown in Sri Lanka. J. Natl. Sci. Found. 2001, 29, 147–153.
  82. Vimalanathan, S.; Hudson, J. Anti-Influenza Virus Activity of Essential Oils and Vapors. Am. J. Essent. Oils Nat. Prod. 2014, 2, 47–53.
  83. Andrade-Ochoa, S.; Nevárez-Moorillón, G.V.; Sánchez-Torres, L.E.; Villanueva-García, M.; Sánchez-Ramírez, B.E.; Rodríguez-Valdez, L.M.; Rivera-Chavira, B.E. Quantitative Structure-Activity Relationship of Molecules Constituent of Different Essential Oils with Antimycobacterial Activity against Mycobacterium tuberculosis and Mycobacterium bovis. BMC Complement. Altern. Med. 2015, 15, 332.
  84. Gülçin, I. Antioxidant Activity of Eugenol: A Structure-Activity Relationship Study. J. Med. Food 2011, 14, 975–985.
  85. Zarubaev, V.v.; Pushkina, E.A.; Borisevich, S.S.; Galochkina, A.v.; Garshinina, A.v.; Shtro, A.A.; Egorova, A.A.; Sokolova, A.S.; Khursan, S.L.; Yarovaya, O.I.; et al. Selection of Influenza Virus Resistant to the Novel Camphor-Based Antiviral Camphecene Results in Loss of Pathogenicity. Virology 2018, 524, 69–77.
  86. Zarubaev, V.v.; Garshinina, A.v.; Volobueva, A.S.; Slita, A.v.; Yarovaya, O.I.; Bykov, V.v.; Leonov, K.A.; Motov, V.S.; Khazanov, V.A.; Salakhutdinov, N.F. Optimization of Application Schedule of Camphecene, a Novel Anti-Influenza Compound, Based on Its Pharmacokinetic Characteristics. Fundam Clin. Pharmacol. 2022, 36, 518–525.
  87. Artyushin, O.I.; Sharova, E.v.; Vinogradova, N.M.; Genkina, G.K.; Moiseeva, A.A.; Klemenkova, Z.S.; Orshanskaya, I.R.; Shtro, A.A.; Kadyrova, R.A.; Zarubaev, V.v.; et al. Synthesis of Camphecene Derivatives Using Click Chemistry Methodology and Study of Their Antiviral Activity. Bioorg. Med. Chem. Lett. 2017, 27, 2181–2184.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback